Previous 10 | Next 10 |
At a news conference Sunday, President Donald Trump announced that the Food and Drug Administration issued an emergency use authorization (EUA) for convalescent plasma therapy as a treatment for hospitalized COVID-19 patients. Convalescent plasma is the liquid component of blood containing antib...
Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +67% on FDA nod for convalescent plasma. More news on: Sonnet BioTherapeutics Holdings, Inc., Liminal BioSciences Inc., ADMA Biologics, Inc., Stocks on the move, , Read more ...
ADMA Biologics ( ADMA ) is a long-term holding of mine that I previously wrote about back in April. At that time, the company had recovered well off its mid-March lows during the broader market sell-off, but ADMA remained significantly below the roughly $4/share level it had been at before. ...
"On the therapeutics front...in our battle against the China virus that will save countless lives, the FDA has issued an emergency use authorization — and that's such powerful term, emergency use authorization — for a treatment known as convalescent plasma," President Trump s...
Convalescent Plasma Stocks To Watch Penny stocks shift in an instant and that could be the case for a few companies this week. Over the weekend, U.S. President Donald Trump announced the emergency authorization of convalescent plasma for COVID-19. At a press briefing that began at 5:30 PM ES...
Processors of antibody-rich convalescent plasma, derived from COVID-19 patients who have recovered from the infection, are under the gun on a delay of the expected emergency use authorization from the FDA for the treatment of COVID-19. More news on: Kamada Ltd., Grifols, S.A., XBiotech I...
Results from a large-scale study involving more than 35K severely ill COVID-19 patients demonstrated that the early administration of convalescent plasma, derived from patients who recovered from the infection and who generated antibodies against SARS-CoV-2, lowered the mortality rate. ...
The following slide deck was published by ADMA Biologics, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Gainers: ADiTx Therapeutics (NASDAQ: ADTX ) +102% . More news on: ADiTx Therapeutics, Inc., American Virtual Cloud Technologies, Inc., NuZee, Inc., Stocks on the move, , Read more ...
ADMA Biologics, Inc. (ADMA) Q2 2020 Results Earnings Conference Call August 5, 2020, 04:30 PM ET Company Participants Michelle Pappanastos - Investor Relations, Argot Partners Adam Grossman - Founder, President and Chief Executive Officer Brian Lenz - Executive Vice President and...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...